Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.48 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.48 |
| ▸ | KIF11 | P52732 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.43 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8860350 | 0.95 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL15318304 | 0.94 | KIF11 (0.49) | SLC6A11SLC6A1KIF11KCNH2 | |
| SCHEMBL1260569 | 0.94 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL6849984 | 0.94 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL887485 | 0.94 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL27051202 | 0.94 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL13427508 | 0.94 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2494966 | 0.94 | SLC6A11 (0.43) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL6570212 | 0.91 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2490410 | 0.90 | SLC6A11 (0.50) | SLC6A11SLC6A1KIF11KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030129589-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. | 2003-07-10 | — | — | US | claimed |
| US-20020042112-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. | 2002-04-11 | — | — | US | claimed |
| EP-0954612-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998020166-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | claimed |
| EP-4683716-A1 | DNA NANODEVICES FOR SPECIFIC AND EFFICIENT DELIVERY OF FUNCTIONAL PAYLOADS TO THE CYTOPLASM AND METHODS OF THEIR USE | Arizona Board of Regents on behalf of Arizona State University (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| CN-119452084-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024196422-A1 | DNA NANODEVICES FOR SPECIFIC AND EFFICIENT DELIVERY OF FUNCTIONAL PAYLOADS TO THE CYTOPLASM AND METHODS OF THEIR USE | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-09-26 | — | — | WO | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| EP-3814494-B1 | HIGH THROUGHPUT ASSEMBLY OF NUCLEIC ACID MOLECULES | THERMO FISHER SCIENT GENEART GMBH (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-20210147830-A1 | HIGH THROUGHPUT ASSEMBLY OF NUCLEIC ACID MOLECULES | THERMO FISHER SCIENTIFIC GENEART GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-1998020020-A2 | HIGH DENSITY IMMOBILIZATION OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| EP-0459176-B1 | Oligophosphates with antiviral activity | BAYER AG (DE) | 1995-09-06 | — | — | EP | disclosed |
| US-5416203-A | VIRICIDES | NORTHWESTERN UNIVERSITY (US) | 1995-05-16 | — | — | US | disclosed |
| US-5169842-A | OLIGOPHOSPHATES WITH AN ANTIVIRAL ACTION | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |
| EP-0428707-A4 | STEROID MODIFIED OLIGONUCLEOTIDES | — | 1992-05-20 | — | — | EP | disclosed |
| EP-0459176-A2 | Oligophosphates with antiviral activity | BAYER AG (DE) | 1991-12-04 | — | — | EP | disclosed |
| EP-0428707-A1 | STEROID MODIFIED OLIGONUCLEOTIDES | NORTHWESTERN UNIVERSITY (US) | 1991-05-29 | — | — | EP | disclosed |
| WO-1990014822-A1 | STEROID MODIFIED OLIGONUCLEOTIDES | NORTHWESTERN UNIVERSITY (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | SLC6A11 4777/4885SLC6A1 4770/4885KIF11 3613/4885 |
| US-20020042112-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | DNA2, DDB1, DNMT3A | SLC6A11 3886/4885SLC6A1 4252/4885KIF11 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.